Novartis announces global partnership with Amgen to develop and commercialize pioneering …

(Thomson Reuters ONE via COMTEX) — Novartis International AG / Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. – The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer’s Disease (AD); Novartis’ oral therapy CNP520 will be the lead molecule – Novartis and Amgen also plan to co-develop and co-commercialize Amgen’s migraine portfolio, including fully human monoclonal antibody AMG 334 with first phase III data expected in 2017 – Partnership reinforces Novartis’ continued commitment to developing and bringing innovative neuroscience treatment options to patients Basel, September 1, 2015 – Novartis announced today that it has entered into a global collaboration with Amgen…


Link to Full Article: Novartis announces global partnership with Amgen to develop and commercialize pioneering …

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!